A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer
- PMID: 1905707
- PMCID: PMC5918486
- DOI: 10.1111/j.1349-7006.1991.tb01894.x
A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer
Abstract
A randomized controlled trial involving 13 institutions in Japan was conducted in order to compare the efficacy of tegafur plus mitomycin C (MMC) (Regimen A) and UFT (a combination of uracil and tegafur at a molar ratio of 4 to 1) plus MMC (Regimen B) for patients with advanced gastric cancer, who had not received any prior cancer chemotherapy. Regimen A (tegafur + MMC) consisted of 5 mg of MMC/m2/week given intravenously, and 500 mg of tegafur/m2/day given orally. Regimen B consisted of the same schedule of MMC and 375 mg of UFT/m2/day given orally. One hundred and eighty-six patients with primary gastric cancer were entered; 183 were eligible and 3 were ineligible for the study. A total of 169 were evaluable for efficacy of the treatment, including 90 patients with Regimen A and 79 with Regimen B. A response rate of 7.8% (7/90 cases) for Regimen A and one of 25.3% (20/79 cases) for Regimen B were obtained, indicating a significantly higher response rate for Regimen B according to the Criteria for Evaluating Efficacy of Chemotherapy/Radiation Therapy in the Treatment of Gastric Cancer (P = 0.004). Regarding side effects, no marked differences in either severity or incidence were observed between the two groups. The group assigned to Regimen B showed a significant survival advantage after adjustment for major prognostic factors using a proportional hazards model (P = 0.0398). Moreover, a close correlation of antitumor effect and survival duration was found when the above criteria were used.
References
-
- ) Fujii , S. , Ikenaka , K. , Fukushima , M. and Shirasaka , T.Effect of uracil and its derivatives on antitumor activity of 5 ‐fluorouracil and 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil . Gann , 69 , 763 – 772 ( 1978. ). - PubMed
-
- ) Fujii , S. , Kitano , S. , Ikenaka , K. and Shirasaka , T.Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1‐ (2 ‐tetrahydrofuryl)‐ 5 ‐fluorouracil and level of 5‐fluorouracil in rodents . Gann , 70 , 209 – 214 ( 1979. ). - PubMed
-
- ) Ogawa , M.An overview of chemotherapy for advanced gastric cancer . In“Diagnosis and Treatment of Upper Gastrointestinal Tumors ”, ed. Friedman M. , Ogawa M. and Kisner D. , pp. 357 – 369 ( 1981. ). Excerpta Medica; , Amsterdam .
-
- ) Kurihara , M. , Shirakabe , H. , Izumi , T. , Miyasaka , K. , Maruyama , T. , Sasaki , Y. , Kobayashi , S. and Kamano , T.X‐ray and endoscopy in the evaluation of gastric cancer chemotherapy . In “ Diagnosis and Treatment of Upper Gastrointestinal Tumors ”, ed. Friedman M. , Ogawa M. and Kisner D. , pp. 428 – 449 ( 1981. ). Excerpta Medica; , Amsterdam .
-
- ) Suga , S. , Kimura , K. , Yoshida , Y. , Horiuchi , T. and Yokoyama , Y.UFTM chemotherapy for gastric cancer: effectiveness and comparison of survival between UFTM and surgical treatment in patients with Borrmann type 4 gastric cancer . In “ Fluoropyrimidines in Cancer Therapy ”, ed. Kimura K. , Fujii S. , Ogawa M. , Bodey G. B. and Alberto P. , pp. 311 – 319 ( 1984. ). Excerpta Medica; , Amsterdam .
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical